A randomized phase 2 study reports efficacy for tislelizumab combined with lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma, with strong objective response rates and continued follow-up needed for durability. The trial adds to the growing use of dual-checkpoint and VEGF-pathway combinations in genetically defined renal cancers. While the dataset size remains typical for a phase 2 program in a rare molecular subgroup, the results matter for clinicians because fh-deficient RCC often has limited standard options. The combination also mirrors a strategy used across other tumor types—pairing PD-1 blockade with angiogenesis inhibition—to boost response rates. Developers will likely focus next on durability, safety management, and biomarker work that can identify which patients benefit most from the regimen.
Get the Daily Brief